POZ™ versus PEG
POZ™ is wholly distinct with important advantages compared to PEG.
|DESIRED POLYMER CHARACTERISTIC||COMMERCIAL BENEFIT||POZ™||PEG|
|Limited cellular uptake in non-target tissues||Potential for improved safety||Concentrates in renal epithelium and multiple tissues (liver, bone marrow, spleen)|
|Non-immunogenic||Improved safety may minimize allergic reactions and attenuation of response for chronic treatments||No. PEG is immunogenic. Approximately 25% of the population has demonstrated pre-formed antibodies to PEG.|
|Ability to increase drug payload and control rates of release||Improved efficacy and compliance via less frequent dosing||Limited|
|Ability to target cells||Potential to increase efficacy while reducing side effects||Challenging chemistry makes this more difficult to achieve|
|Low viscosity||Easier preparation and administration to patients||No|
|Ease of synthesis||Faster and safer drug synthesis may prove more economical||No. Requires explosive starting materials|
|Stability (storage and reconstitution)||Less waste||BHT required to prevent oxidization|
|Strong IP||Broad market exclusivity||Crowded patent estate|
|Ability to attach different drug classes||Provides broader optimization for therapeutic candidates|
|Renal clearance||Does not undergo metabolism in the body and is excreted unchanged|
Serina therapeutics has a robust patent estate that includes twelve issued patents worldwide and twenty-four patents pending.